FZD5 (Frizzled Class Receptor 5) is a transmembrane receptor belonging to the Frizzled family of G protein-coupled receptors (GPCRs). The FZD5 protein is encoded by the FZD5 gene located on chromosome 2q33.3 in humans. As a seven-transmembrane spanning receptor, FZD5 functions as a key component of the Wnt signaling pathway, one of the most evolutionarily conserved cell-cell communication systems. Frizzled receptors like FZD5 serve as primary ligand-binding partners for Wnt proteins, which are secreted glycoproteins essential for developmental patterning, cell proliferation, and neuronal homeostasis. The protein's structure consists of an extracellular cysteine-rich domain (CRD) responsible for Wnt protein binding, seven hydrophobic transmembrane domains, and intracellular loops that facilitate signal transduction through multiple downstream effectors.
Function/Biology
...
FZD5 Protein
Overview
FZD5 (Frizzled Class Receptor 5) is a transmembrane receptor belonging to the Frizzled family of G protein-coupled receptors (GPCRs). The FZD5 protein is encoded by the FZD5 gene located on chromosome 2q33.3 in humans. As a seven-transmembrane spanning receptor, FZD5 functions as a key component of the Wnt signaling pathway, one of the most evolutionarily conserved cell-cell communication systems. Frizzled receptors like FZD5 serve as primary ligand-binding partners for Wnt proteins, which are secreted glycoproteins essential for developmental patterning, cell proliferation, and neuronal homeostasis. The protein's structure consists of an extracellular cysteine-rich domain (CRD) responsible for Wnt protein binding, seven hydrophobic transmembrane domains, and intracellular loops that facilitate signal transduction through multiple downstream effectors.
Function/Biology
FZD5 operates as a molecular hub integrating Wnt signaling into multiple cellular pathways. Upon binding Wnt ligands—particularly Wnt3a, Wnt5a, and Wnt7a in neuronal contexts—FZD5 undergoes conformational changes that activate intracellular signaling cascades. The receptor can transduce signals through both canonical (β-catenin-dependent) and non-canonical (β-catenin-independent) Wnt pathways. In the canonical pathway, FZD5 recruits the co-receptor LDL receptor-related protein (LRP5/6), leading to inhibition of glycogen synthase kinase-3β (GSK-3β) and stabilization of β-catenin, which subsequently translocates to the nucleus to regulate transcription via LEF/TCF transcription factors. Non-canonical signaling through FZD5 can activate planar cell polarity (PCP) pathways involving Rho/Rac GTPases and c-Jun N-terminal kinase (JNK), as well as Wnt-calcium pathways triggering intracellular calcium mobilization and calmodulin-dependent kinase II (CaMKII) activation.
Role in Neurodegeneration
FZD5 has emerged as a critical player in multiple neurodegenerative disease mechanisms. In Alzheimer's disease, dysregulation of Wnt signaling through FZD5 impairs synaptic plasticity and promotes amyloid-beta (Aβ) accumulation. Studies have demonstrated that reduced Wnt-FZD5 signaling correlates with decreased levels of synaptic proteins and increased neuroinflammatory responses. The protein's role in maintaining neuronal architecture and connectivity is compromised during pathological aging, contributing to cognitive decline. In Parkinson's disease, FZD5-mediated signaling influences dopaminergic neuron survival and dopamine production; loss of Wnt signaling reduces expression of tyrosine hydroxylase and increases vulnerability to oxidative stress. FZD5 dysfunction has also been implicated in ALS pathogenesis, where impaired Wnt signaling compromises motor neuron survival and neuromuscular junction integrity. Additionally, in Huntington's disease, aberrant FZD5 signaling may contribute to striatal vulnerability and exacerbate mutant huntingtin protein toxicity.
Molecular Mechanisms
At the molecular level, FZD5 dysfunction in neurodegeneration involves several mechanisms. Aberrant phosphorylation of FZD5 itself or its binding partners disrupts signal transduction efficiency. Dysregulation of GSK-3β activity—a key regulator of multiple pathways—occurs when FZD5 signaling is compromised, leading to increased tau hyperphosphorylation and amyloid-beta generation in Alzheimer's disease. FZD5 signaling also modulates neuroinflammatory responses by regulating nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and pro-inflammatory cytokine production. Mitochondrial dysfunction associated with reduced FZD5 signaling impairs cellular energy metabolism and increases reactive oxygen species generation. Additionally, FZD5 influences autophagy and proteasomal degradation pathways essential for clearing protein aggregates characteristic of neurodegenerative diseases.
Clinical/Research Significance
FZD5 represents both a biomarker and therapeutic target for neurodegenerative diseases. Research indicates that FZD5 expression levels inversely correlate with disease severity in several conditions. Pharmacological approaches to enhance Wnt-FZD5 signaling, including small-molecule Wnt pathway activators and monoclonal antibodies targeting negative regulators like dickkopf proteins, show promise in preclinical models. Understanding FZD5 biology informs development of neuroprotective therapies aimed at preserving neuronal integrity and function.
Related Entities
Wnt Signaling Pathway: Primary signaling cascade activated by FZD5
LRP5/6: Co-receptors essential for canonical Wnt-FZD5 signaling